Century Therapeutics (IPSC) said Thursday it appointed Chad Cowan chief scientific officer, effective Oct. 1, and Morgan Conn chief financial officer, effective Oct. 14.
Cowan previously served as an executive scientific adviser of the company, following the acquisition of Clade Therapeutics in April 2024, where he was founder and CEO.
Meanwhile, Conn was the chief business officer at Pharvaris prior to joining Century.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.